Taylor Sandison
Technik-/Wissenschafts-/F&E-Leiter bei CIDARA THERAPEUTICS, INC.
Vermögen: 139 831 $ am 31.05.2024
Profil
Taylor Sandison's current job is Chief Medical Officer at Cidara Therapeutics, Inc. Dr. Sandison's former jobs include Senior Medical Director at Merck & Co., Inc., Senior Medical Director at Cubist Pharmaceuticals LLC, Director-Medical Affairs at Novartis Vaccines & Diagnostics, Inc., and Director-Clinical Science at Trius Therapeutics, Inc. Dr. Sandison's education includes an undergraduate degree from Dartmouth College, a doctorate degree from the University of Washington (conferred in 2001), and a graduate degree from the University of Washington (conferred in 2007).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.05.2024 | 11 019 ( 0,24% ) | 139 831 $ | 31.05.2024 |
Aktive Positionen von Taylor Sandison
| Unternehmen | Position | Beginn |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 |
Ehemalige bekannte Positionen von Taylor Sandison
| Unternehmen | Position | Ende |
|---|---|---|
| MERCK & CO., INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2015 |
| CUBIST PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2015 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2014 |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2013 |
Ausbildung von Taylor Sandison
| Dartmouth College | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CIDARA THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Health Technology |
